Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of paclitaxel plus anti-EGFR as a second-line therapy for gastric and gastroesophageal junction adenocarcinomas
KCT0004314Phase 2Recruiting
- Sponsor
- GC Biopharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by GC Biopharma. Started Sep 2019; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0004314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004314.